A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo
Science Translational Medicine · 2023
DOI: 10.1126/scitranslmed.adf4549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Clare Burn Aschner und 19 weiteren Autor:innen. Beteiligte Einrichtung: Program in Molecular Medicine, Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada. Hauptthemen laut MEDLINE: Severe acute respiratory syndrome-related coronavirus, COVID-19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 92 Literaturangaben.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has been responsible for a global pandemic. Monoclonal antibodies (mAbs) have been used as antiviral therapeutics; however, these therapeutics have been limited in efficacy by viral sequence variability in emerging variants of concern (VOCs) and in deployment by the need for high doses. In this study, we leveraged the multi-specific, multi-affinity antibody (Multabody, MB) platform, derived from the human apoferritin protomer, to enable the multimerization of antibody fragments. MBs were shown to be highly potent, neutralizing SARS-CoV-2 at lower concentrations than their corresponding mAb counterparts. In mice infected with SARS-CoV-2, a tri-specific MB targeting three regions within the SARS-CoV-2 receptor binding domain was protective at a 30-fold lower dose than a cocktail of the corresponding mAbs. Furthermore, we showed in vitro that mono-specific MBs potently neutralize SARS-CoV-2 VOCs by leveraging augmented avidity, even when corresponding mAbs lose their ability to neutralize potently, and that tri-specific MBs expanded the neutralization breadth beyond SARS-CoV-2 to other sarbecoviruses. Our work demonstrates how avidity and multi-specificity combined can be leveraged to confer protection and resilience against viral diversity that exceeds that of traditional monoclonal antibody therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program in Molecular Medicine, Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada.
- Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
- Combined Containment Level 3 Unit, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
- Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
ORCID-Profile: Clare Burn Aschner, Krithika Muthuraman, Iga Kucharska, Manoj S Nair, Yaoxing Huang, Natasha Christie-Holmes, Jessica Lam, Samira Mubareka, John L Rubinstein, Edurne Rujas, Bebhinn Treanor, David D Ho, Arif Jetha, Jean-Philippe Julien
Zitieren
APA
Burn Aschner, C., Muthuraman, K., Kucharska, I., Cui, H., Prieto, K., Nair, M. S., Wang, M., Huang, Y., Christie-Holmes, N., Poon, B., Lam, J., Sultana, A., Kozak, R., Mubareka, S., Rubinstein, J. L., Rujas, E., Treanor, B., Ho, D. D., Jetha, A., & Julien, J. P. (2023). A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adf4549
Vancouver
Burn Aschner C, Muthuraman K, Kucharska I, Cui H, Prieto K, Nair MS, et al. A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.adf4549
BibTeX
@article{BurnAschner2023,
author = {Burn Aschner, Clare and Muthuraman, Krithika and Kucharska, Iga and Cui, Hong and Prieto, Katherine and Nair, Manoj S and Wang, Maple and Huang, Yaoxing and Christie-Holmes, Natasha and Poon, Betty and Lam, Jessica and Sultana, Azmiri and Kozak, Robert and Mubareka, Samira and Rubinstein, John L and Rujas, Edurne and Treanor, Bebhinn and Ho, David D and Jetha, Arif and Julien, Jean-Philippe},
title = {A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo},
journal = {Science Translational Medicine},
year = {2023},
doi = {10.1126/scitranslmed.adf4549}
}
EUVIMED